Summary
Alnylam Pharmaceuticals, Inc. (ALNY) filed an 8-K on October 10, 2018, primarily to announce changes to its Board of Directors and the appointment of a new Principal Accounting Officer. These changes are effective January 10, 2019, following the resignation of director John K. Clarke. Margaret A. Hamburg has been elected to fill the vacancy and will receive standard compensation for non-employee directors, including cash fees and stock options. Furthermore, Chief Financial Officer Manmeet S. Soni has been appointed as the Company's Principal Accounting Officer, in addition to his existing roles. Michael P. Mason will be relinquishing this specific duty but will continue in his VP of Finance role. Investors should note that these are administrative and governance changes, with no immediate impact on the company's operational or financial performance, but they reflect ongoing board evolution and accounting oversight responsibilities.
Key Highlights
- 1John K. Clarke resigned from the Board of Directors, effective January 10, 2019. His resignation was not due to any disagreements.
- 2Margaret A. Hamburg was elected to fill the Board vacancy created by Mr. Clarke's resignation, effective January 10, 2019.
- 3Ms. Hamburg will receive $50,000 annually in cash fees and stock options as compensation for her role as a non-employee director.
- 4Manmeet S. Soni, the current CFO, has been appointed as the Company's Principal Accounting Officer, effective October 9, 2018.
- 5Michael P. Mason will no longer serve as Principal Accounting Officer but will continue as VP, Finance, focusing on commercial finance.
- 6The Audit Committee composition will change with Colleen F. Reitan becoming a member upon Mr. Clarke's departure.